Literature DB >> 26713891

Review of genotoxicity and rat carcinogenicity investigations with astaxanthin.

James A Edwards1, Phillip Bellion2, Paul Beilstein3, Robert Rümbeli4, Joseph Schierle5.   

Abstract

Synthetic astaxanthin has been extensively tested for safety. Genotoxicity studies including Ames and in vitro Micronucleus Tests show absence of genotoxic potential. Although a long-term mouse study showed no carcinogenicity potential, the rat carcinogenicity study with dietary dosages of 0 (control), 0 (placebo beadlet), 40, 200 and 1000 mg astaxanthin/kg bw/day showed an increased incidence of benign, hepatocellular adenoma in females only, at 200 mg/kg bw/day and above. There was no clear evidence of toxicity during the in-life phase. Discoloration of feces was observed and a reduction in body weight gain in all groups receiving beadlets, probably reflecting a nutritional influence. Blood sampling confirmed systemic exposure and some minor clinical chemistry differences in females at 200 and 1000 mg/kg bw/day. There was no effect on adjusted liver weight. Histopathological examination showed hepatic changes indicative of slight hepatotoxicity and hepatocyte regeneration in females at 200 and 1000 mg/kg bw/day, in addition to the adenoma. Taking into account this pathological background in the female rat, and a wide variety of other supporting information, it is concluded that the hepatocellular adenoma in female rats was secondary to hepatotoxicity and regeneration, and is most probably a species-specific phenomenon of doubtful human relevance.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ames test; Astaxanthin; Carcinogenicity; Clastogenicity; Genotoxicity; Hepatocellular adenoma; Hepatotoxicity; Micronucleus test; Mutagenicity; Rat

Mesh:

Substances:

Year:  2015        PMID: 26713891     DOI: 10.1016/j.yrtph.2015.12.009

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  6 in total

Review 1.  Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals.

Authors:  Elizabeth M Williamson; Xinmin Liu; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2020-02-06       Impact factor: 8.739

Review 2.  Recent Advances and the Mechanism of Astaxanthin in Ophthalmological Diseases.

Authors:  Ming Yang; Yanling Wang
Journal:  J Ophthalmol       Date:  2022-05-20       Impact factor: 1.974

3.  Optimization of Astaxanthin Recovery in the Downstream Process of Haematococcus pluvialis.

Authors:  Inga K Koopmann; Simone Möller; Clemens Elle; Stefan Hindersin; Annemarie Kramer; Antje Labes
Journal:  Foods       Date:  2022-05-06

Review 4.  Astaxanthin in Liver Health and Disease: A Potential Therapeutic Agent.

Authors:  Jingjing Li; Chuanyong Guo; Jianye Wu
Journal:  Drug Des Devel Ther       Date:  2020-06-09       Impact factor: 4.162

5.  Safety and efficacy of a feed additive consisting of astaxanthin-rich Phaffia rhodozyma for salmon and trout (Igene Biotechnology, Inc.).

Authors:  Vasileios Bampidis; Giovanna Azimonti; Maria de Lourdes Bastos; Henrik Christensen; Birgit Dusemund; Mojca Fašmon Durjava; Maryline Kouba; Marta López-Alonso; Secundino López Puente; Francesca Marcon; Baltasar Mayo; Alena Pechová; Mariana Petkova; Fernando Ramos; Yolanda Sanz; Roberto Edoardo Villa; Ruud Woutersen; Jaume Galobart; Orsolya Holcznecht; Maria Vittoria Vettori
Journal:  EFSA J       Date:  2022-02-24

Review 6.  What Do We Know about Antimicrobial Activity of Astaxanthin and Fucoxanthin?

Authors:  Tomasz M Karpiński; Marcin Ożarowski; Rahat Alam; Małgorzata Łochyńska; Mark Stasiewicz
Journal:  Mar Drugs       Date:  2021-12-29       Impact factor: 5.118

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.